SUCCESSFUL MANAGEMENT OF MALIGNANT HYPERTHERMIA AVOIDING THE USE OF DANTROLENE (a clinical case)
https://doi.org/10.21292/2078-5658-2018-15-1-63-69
Abstract
The article describes the clinical case when malignant hyperthermia was diagnosed in the patients during the cardiac surgery. The patient had anesthesia with desflurane. The state of the patient was stabilized due to timely diagnostics and aggressive therapy with non-specific agents and cardiopulmonary bypass. The article presents different variants of clinical manifestations of this complication, ways of diagnostics and specific therapy.
About the Authors
A. A. Khryapa
Pavlov First Saint Petersburg State Medical University
Russian Federation
Candidate of Medical Sciences, Head of Anesthesiology and Intensive Care Department of Research Clinical Center of Anesthesiology and Intensive Care
Russian Federation
Candidate of Medical Sciences, Head of Anesthesiology and Intensive Care Department of Research Clinical Center of Anesthesiology and Intensive Care
K. N. Khrapov
Pavlov First Saint Petersburg State Medical University
Russian Federation
Doctor of Medical Sciences, Head of Anesthesiology Department of Research Clinical Center of Anesthesiology and Intensive Care, Professor of Anesthesiology and Intensive Care Department
Russian Federation
Doctor of Medical Sciences, Head of Anesthesiology Department of Research Clinical Center of Anesthesiology and Intensive Care, Professor of Anesthesiology and Intensive Care Department
I. V. Shlyk
Pavlov First Saint Petersburg State Medical University
Russian Federation
Doctor of Medical Sciences, Deputy Head Doctor for Anesthesiology and Intensive Care, Deputy Head of Anesthesiology and Intensive Care Research Clinical Center, Professor of Anesthesiology and Intensive Care Department
Russian Federation
Doctor of Medical Sciences, Deputy Head Doctor for Anesthesiology and Intensive Care, Deputy Head of Anesthesiology and Intensive Care Research Clinical Center, Professor of Anesthesiology and Intensive Care Department
N. S. Smolin
Pavlov First Saint Petersburg State Medical University
Russian Federation
Student of the 6th year, Member of Students' Research Society by Anesthesiology and Intensive Care Department
Russian Federation
Student of the 6th year, Member of Students' Research Society by Anesthesiology and Intensive Care Department
V. D. Nazarov
Pavlov First Saint Petersburg State Medical University
Russian Federation
Junior Researcher of Laboratory for Diagnostics of Autoimmune Diseases of Research Center of Molecular Medicine
Russian Federation
Junior Researcher of Laboratory for Diagnostics of Autoimmune Diseases of Research Center of Molecular Medicine
A. A. Musaelyan
Pavlov First Saint Petersburg State Medical University
Russian Federation
Student of the 4th year, Member of Students' Molecular Medicine Research Society
Russian Federation
Student of the 4th year, Member of Students' Molecular Medicine Research Society
S. V. Lapin
Pavlov First Saint Petersburg State Medical University
Russian Federation
Candidate of Medical Sciences, Head of Laboratory for Diagnostics of Autoimmune Diseases of Research Center of Molecular Medicine
Russian Federation
Candidate of Medical Sciences, Head of Laboratory for Diagnostics of Autoimmune Diseases of Research Center of Molecular Medicine
References
1. Evans T.J., Parent C.M., McGunigal M.P. Atypical presentation of malignant hyperthermia. Anesthesiology, 2002, vol. 97, no. 2, pp. 507‒508.
2. Glahn K.P., Ellis F.R., Halsall P.J. et al. European Malignant Hyperthermia Group. Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. Br. J. Anaesth., 2010, vol. 105, no. 4, pp. 417‒420.
3. Gronert G.A. Malignant hyperthermia. Anesthesiology, 1980, vol. 53, no. 5, pp. 395‒423.
4. Hopkins P.M. Rüffert H., Snoeck M.M. et al. Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. Br. J. Anaesth., 2015, vol. 115, no. 4, pp. 531‒539.
5. Hopkins P.M. Malignant hyperthermia: advances in clinical management and diagnosis. Br. J. Anaesth., 2000, vol. 85, no. 1, pp. 118-128.
6. http://www.mhaus.org/healthcare-professionals/ mhaus-recommendations/temperature-monitoring (Accessed on May 21, 2015).
7. Huh H., Jung J.S., Park S.J. et al. Successful early application of extracorporeal membrane oxygenation to support cardiopulmonary resuscitation for a patient suffering from severe malignant hyperthermia and cardiac arrest: a case report. Korean J. Anesthesiol., 2017, vol. 7, no. 3, pp. 345‒349.
8. Klingler W., Rueffert H., Lehmann-Horn F. et al. Core myopathies and risk of malignant hyperthermia. Anesth. Analg., 2009, vol. 109, no. 4, pp. 1167–1173.
9. Larach M.G., Brandom B.W., Allen G.C. et al. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007‒2012: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States. Anesth Analg., 2014, vol. 119, no. 6, pp. 1359‒1366.
10. Larach M.G., Gronert G.A., Allen G.C. et al. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth. Analg., 2010, vol. 110, no. 2, pp. 498‒507.
11. Larach M.G., Localio A.R., Allen G.C. et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology, 1994, vol. 80, no. 4, pp. 771‒779.
12. Litman R.S., Flood C.D., Kaplan R.F. et al. Postoperative malignant hyperthermia: an analysis of cases from the North American Malignant Hyperthermia Registry. Anesthesiology, 2008, vol. 109, no. 5, pp. 825‒829.
13. Louis C.F., Zualkernan K., Roghair T., Mickelson J.R. The effects of volatile anesthetics on calcium regulation by malignant hyperthermia-susceptible sarcoplasmic reticulum. Anesthesiology, 1992, vol. 77, no. 1, pp. 114‒125.
14. O'Sullivan G.H., McIntosh J.M., Heffron J.J. Abnormal uptake and release of Ca2+ ions from human malignant hyperthermia-susceptible sarcoplasmic reticulum. Biochem Pharmacol., 2001, vol. 61, no. 12, pp. 1479‒1485.
15. Rosenberg H., Davis M., James D. et al. Malignant hyperthermia. Orphanet. J. Rare Dis., 2007, vol. 2, pp. 21‒35.
16. Rosenberg H., Fletcher J.E. An update on the malignant hyperthermia syndrome. Ann Acad Med Singapore, 1994, vol. 23, no. 6, pp. 84‒97.
17. Rosenberg H., Pollock N., Schiemann A. et al. Malignant hyperthermia: a review. Orphanet. J. Rare Dis., 2015, vol. 10, pp. 93‒112.
18. Sambuughin N., Holley H., Muldoon S. et al. Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the north american population. Anesthesiology, 2005, vol. 102, no. 3, pp. 515‒521.
19. Studo R.T., Cunha L.B., Carmo P.L. et al. Use of the caffeine halothane contracture test for the diagnosis of malignant hyperthermia in Brazil. Braz. J. Med. Biol. Res., 2010, vol. 43, no. 6, pp. 549‒556.
20. Zhao F., Li P., Chen S.R. et al. Dantrolene inhibition of ryanodine receptor Ca2+ release channels: Molecular mechanism and isoform selectivity. J. Biol. Chem., 2001, vol. 276, no. 17, pp. 13810‒13816.
Review
For citations:
Khryapa A.A., Khrapov K.N., Shlyk I.V., Smolin N.S., Nazarov V.D., Musaelyan A.A., Lapin S.V. SUCCESSFUL MANAGEMENT OF MALIGNANT HYPERTHERMIA AVOIDING THE USE OF DANTROLENE (a clinical case). Messenger of ANESTHESIOLOGY AND RESUSCITATION. 2018;15(1):63-69. (In Russ.) https://doi.org/10.21292/2078-5658-2018-15-1-63-69
Email this article 